Earnings Results
Grace Therapeutics (NASDAQ:GRCE) reported quarterly earnings results on August 13, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.91, missing the consensus estimate of $-0.18 by $0.73 per share. Revenue came in at , missing the estimate of $545.0K.
Company Overview
Grace Therapeutics's stock moved following the earnings release. The stock currently trades at $2.11 with a market capitalization of $47.5M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 406% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Grace Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Grace Therapeutics Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q1 (Aug 2026) | $-0.91 | $-0.18 | -405.6% |
| Q4 (Jun 2026) | $-0.06 | $-0.21 | +71.4% |
| Q3 (Feb 2026) | $-0.14 | $-0.27 | +48.1% |
| Q2 (Sep 2025) | $-0.06 | $-0.19 | +68.2% |
Related Tools: Earnings Calendar | View GRCE Stock Page
Frequently Asked Questions
When does Grace Therapeutics report earnings?
Check the latest earnings dates on our GRCE earnings page or the Earnings Calendar.
Did GRCE beat earnings estimates?
See the full Q1 results including EPS actual vs estimate on our GRCE earnings page.